Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: real-world evidence from a 22-year follow-up study
Akerkar A, Rønn PF, Kosjerina V, et al.
Diabetes Obes Metab. Pub. online 22 Jan 2025.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Association between sarcopenia and weight-adjusted waist index in male patients with type 2 diabetes
Xiang Y, Wang Z, Xu J, et al.
BMC Endocr Disord. 2025;25(1):20.
Leggi
Bariatric surgery and cardiovascular outcomes in patients with obesity, metabolic dysfunction-associated steatotic liver disease, and coronary artery disease: a population-based matched cohort study
Krishnan A, Sims OT, Teran D, et al.
Eur Heart J Qual Care Clin Outcomes. 2025:qcaf001.
Leggi
Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes
Mueller J, Breeze P, Fusco F, et al.
Diabetologia. Pub. online 23 Jan 2025.
Leggi
Risk of renal complications and death in young and middle-aged Swedes with parental type 1 diabetes: a nation-wide, prospective cohort study
Fredriksson M, Persson E, Möllsten A, Lind T
BMJ Open Diabetes Res Care. 2025;13(1):e004709.
Leggi
Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors
Shin H, Paik JM, Everett BM, et al.
JAMA Intern Med. Pub. online 21 Jan 2025.
Leggi
Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers
Collins J, Farnsworth NL
Diabetologia. Pub. online 23 Jan 2025.
Abstract
Leggi
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Davies MJ, van der Meer P, Verma S, Patel S, et al.
Lancet Diabetes Endocrinol. Pub. online 20 Jan 2025.
Leggi
Effectiveness of empagliflozin vs dapagliflozin for kidney outcomes in type 2 diabetes
Bonnesen K, Heide-Jørgensen U, Christensen DH
JAMA Intern Med. Pub. online 21 Jan 2025.
Leggi
Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study
Abdullah Z, Cui Y, Platt RW, et al.
BMJ Open Diabetes Res Care. 2025;13(1):e004541.
Leggi